Table 2. Adverse effects of chemotherapy in patients after two cycles of pemetrexed therapy.
| Adverse event | All grades, n (%) | Grade 1–2, n (%) | Grade 3–4, n (%) | Grade 5, n (%) |
|---|---|---|---|---|
| ALT increased | 4 (13.8) | 4 (13.8) | 0 | 0 |
| AST increased | 4 (13.8) | 4 (13.8) | 0 | 0 |
| Decreased platelet count | 2 (6.89) | 1 (3.45) | 1 (3.45) | 0 |
| Decreased leukocyte count | 7 (24.1) | 4 (13.8) | 3 (10.3) | 0 |
| Decreased neutrophil count | 5 (17.2) | 3 (10.3) | 2 (6.9) | 0 |
| Decreased hemoglobin count | 4 (13.8) | 1 (3.45) | 3 (10.3) | 0 |
| Nausea | 15 (51.7) | 11 (37.9) | 4 (13.8) | 0 |
| Vomit | 9 (31.0) | 5 (17.2) | 4 (13.8) | 0 |
| Alexithymia | 6 (20.1) | 4 (13.8) | 2 (6.9) | 0 |
| Diarrhea | 5 (17.2) | 4 (13.8) | 1 (3.45) | 0 |
| Fatigue | 13 (44.8) | 3 (10.3) | 10 (34.5) | 0 |
| Fever | 2 (6.9) | 2 (6.9) | 0 | 0 |
| Rash | 6 (20.1) | 1 (3.45) | 5 (17.2) | 0 |
| Oral mucositis | 5 (17.2) | 3 (10.3) | 2 (6.9) | 0 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.